News

Devyser receives Eurostars grant to develop novel DNA test for early detection of transplant rejection

Devyser has been awarded a funding of EUR 750,000 through the Eurostars-2 program and will join its efforts with the University Hospital of Zurich to further develop its unique NGS based test for early detection of kidney transplant recipients. Through this project, Devyser aims to provide a certified CE-IVD kit, including reagents, protocols and software …

Devyser receives Eurostars grant to develop novel DNA test for early detection of transplant rejection Read More »

Case Study – A new NGS-based method for chimerism monitoring

New methods for mixed chimerism analytics are transforming post-transplant monitoring, enabling earlier detection of relapse and initiation of treatment to improve and save the lives of transplanted patients. Dr. Dan Hauzenberger, Medical Director, Section of Transplantation Immunology at Sweden’s Karolinska University Hospital, shares why Karolinska decided to replace their STR-PCR and qPCR methods with a …

Case Study – A new NGS-based method for chimerism monitoring Read More »

Devyser at DGTI 2020

Come and visit our virtual booth at DGTI! The 53rd annual meeting in Immunohaematology and Transfusion Medicine is taking place virtually from September 16th to 18th 2020. Visit our virtual booth to learn more about our upcoming solution for the non-invasive detection of fetal RHD status as well as Devyser Chimerism, our chimerism monitoring solution. …

Devyser at DGTI 2020 Read More »

Devyser’s breakthrough NGS product for hereditary breast and ovarian cancer testing now approved for diagnostic use in the EU

Stockholm, 22 July 2020 —Swedish genetic test developer Devyser’s product for hereditary breast and ovarian cancer (HBOC) is now CE labelled and approved for diagnostic use in the EU. The kit is based on Devyser’s patented next-generation sequencing library prep technology and provides targeted sequencing of 12 genes with a recognized connection to the development …

Devyser’s breakthrough NGS product for hereditary breast and ovarian cancer testing now approved for diagnostic use in the EU Read More »

Discover Devyser CFTR 68

https://vimeo.com/434385139/77bd5832b6 Discover Devyser CFTR 68, our latest kit for the analysis of the CFTR gene, capable of detecting up to 68 mutations most commonly associated with Cystic Fibrosis. List of mutations detected by Devyser CFTR 68 711+ 1G>T, 2043delG, 1677delTA, W1282X, R1283M, K710X, 3849+10kbC>T, 2789+5G>A, M1101K, G85E, 3905insT, 1525-1G>A, 2184delA, 3659delC, N1303K, 2184insA, 1812-1G->A, CFTRdele2,3, …

Discover Devyser CFTR 68 Read More »

Devyser gears up for global sales of genetic tests — recruits Torbjörn Andersson as Chief Commercial Officer

Stockholm, 26 may 2020 — Devyser welcomes Torbjörn Andersson as Chief Commercial Officer in charge of global sales and marketing of Devyser’s genetic tests. Torbjörn has extensive experience in building and leading international sales organisations and distributor networks in the life science industry. He joins us most recently from Biotage AB where he was the Head …

Devyser gears up for global sales of genetic tests — recruits Torbjörn Andersson as Chief Commercial Officer Read More »